Showing results (121-130 of 145) with videos related to

Sort By:
Pageof 15
JAMA Oncology|June 15, 2018
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical TrialGlenwood D Goss, Enriqueta Felip, Manuel Cobo, et al.
Heliyon|July 25, 2024
Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancerMaría Zapata-García, Alba Moratiel-Pellitero, Dolores Isla, et al.
International Journal of Molecular Sciences|July 28, 2026
Soluble Immune Checkpoints as Prognostic Biomarkers in Small Cell Lung Cancer Patients Treated with Chemotherapy and Anti-PD-L1Albert Guinart-Cuadra, Aida Piedra, Sergio Martínez-Recio, et al.
Tumori|April 26, 2007
Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancerJose Ignacio Mayordomo, Raquel Andres, Maria Dolores Isla, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2021
Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selectionMariano Provencio, Margarita Majem, María Guirado, et al.
Frontiers in Artificial Intelligence|May 6, 2026
Brief report: Artificial intelligence meets small cell lung cancer-integrating clinicopathological and wholeslide image data for prognostic prediction in SCLCPedro Rocha, Joan Gibert, Silvía Menendez, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study)Dolores Isla, Ramón De Las Peñas, Amelia Insa, et al.
Plos One|May 6, 2009
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expressionRafael Rosell, Laia Perez-Roca, Jose Javier Sanchez, et al.
Cell Reports. Medicine|June 21, 2025
MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancerRaúl Del Rey-Vergara, Miguel Alejandro Galindo-Campos, Pedro Rocha, et al.
The New England Journal of Medicine|August 21, 2009
Screening for epidermal growth factor receptor mutations in lung cancerRafael Rosell, Teresa Moran, Cristina Queralt, et al.
Pageof 15